Welcome to our dedicated page for INVVY news (Ticker: INVVY), a resource for investors and traders seeking the latest updates and insights on INVVY stock.
INVVY (INVVY) is a pharmaceutical innovator developing emergency treatments for opioid overdoses and substance use disorders. This news hub provides investors and healthcare professionals with essential updates about the company's clinical advancements, regulatory milestones, and market developments.
Access real-time updates on INVVY's intranasal opioid antagonists, pharmacodynamic research breakthroughs, and global distribution partnerships. Our curated feed includes earnings reports, product launch announcements, and strategic collaborations impacting emergency medicine and addiction treatment markets.
Key coverage areas include clinical trial results, FDA regulatory updates, intellectual property developments, and healthcare partnership announcements. All content is verified through primary sources to ensure accuracy in this fast-evolving therapeutic sector.
Bookmark this page for streamlined access to INVVY's latest developments in opioid crisis response and evidence-based addiction therapies. Check regularly for updates on life-saving pharmaceutical innovations and their market implications.
Indivior, a leading addiction treatment company, will host an analyst teach-in event in New York City, confirming its FY 2024 guidance. The company expects net revenue between $1,240m and $1,330m, an 18% increase from FY 2023. SUBLOCADE revenue is projected at $820m to $880m, a 35% rise. OPVEE revenue is anticipated to be $15m to $25m, and PERSERIS revenue is forecasted at $55m to $65m, a 43% increase. SUBOXONE Film market share is expected to decline by 1-2 percentage points. Adjusted gross margin is estimated to be in the low to mid-80s range.
Adjusted SG&A expenses are projected at $575m to $590m, with R&D expenses between $120m and $130m. Adjusted operating profit is expected to be $330m to $380m. The event will be webcast and aims to provide an in-depth overview of Indivior's growth and value creation strategies.
FAQ
What is the market cap of INVVY (INVVY)?
